Crestor vs Leqvio: Long-Term Durability of LDL-C Response

How Each Drug Lowers LDL-C

Rosuvastatin and inclisiran reduce LDL-C through entirely different mechanisms, and understanding those mechanisms explains why their durability profiles diverge so sharply over time.

Rosuvastatin: HMG-CoA Reductase Inhibition

Rosuvastatin blocks HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis [1]. The liver compensates by upregulating LDL receptors, pulling more LDL-C out of circulation. At 20 mg daily, rosuvastatin reduces LDL-C by approximately 52% from baseline [2]. At 40 mg, reductions reach 55 to 63% in clinical trials [3]. The drug's half-life is about 19 hours, meaning a single missed dose causes plasma levels to fall below therapeutic range within 24 to 36 hours [4].

That pharmacokinetic dependency is the core durability problem. Every day without the pill is a day the LDL receptor upregulation partially reverses.

Inclisiran: RNA Interference of PCSK9

Inclisiran is a small interfering RNA (siRNA) that targets PCSK9 messenger RNA inside hepatocytes [5]. By silencing PCSK9 production at the transcriptional level, inclisiran prevents PCSK9 from degrading LDL receptors. The result is sustained receptor recycling and continuous LDL-C clearance. Because the mechanism operates at the mRNA level rather than requiring ongoing plasma drug concentration, a single injection sustains effect for roughly six months [6].

The FDA approved inclisiran (Leqvio) in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering [7]. Dosing is a 284 mg subcutaneous injection on day 1, day 90, then every six months.

JUPITER and ORION: What the Trials Actually Show

These two trial programs are the primary sources of long-term efficacy data for each drug, and reading them side by side clarifies where each agent performs best.

JUPITER (Rosuvastatin in Primary Prevention)

JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) enrolled 17,802 apparently healthy adults with LDL-C below 130 mg/dL but elevated hsCRP (2.0 mg/L or higher) [2]. Participants received rosuvastatin 20 mg or placebo. The trial was stopped early at a median follow-up of 1.9 years because rosuvastatin reduced the primary composite endpoint (MI, stroke, arterial revascularization, hospitalization for unstable angina, or CV death) by 44% (HR 0.56, 95% CI 0.46 to 0.69, P<0.00001) [2].

LDL-C dropped from a median of 108 mg/dL at baseline to 55 mg/dL on rosuvastatin, a 50% median reduction. That number reflects performance under trial conditions, with supervised adherence and frequent monitoring visits.

Real-world data tell a different story. A 2016 analysis in the Annals of Internal Medicine found that statin adherence fell to approximately 50% by 12 months in community pharmacy claims databases, with the steepest drop occurring in the first 90 days [8].

ORION-10 and ORION-11 (Inclisiran in ASCVD)

ORION-10 (N=1,561, United States) and ORION-11 (N=1,617, Europe and South Africa) were Phase 3 placebo-controlled trials in patients with ASCVD or ASCVD risk equivalents who were on maximally tolerated statin therapy [9]. Inclisiran 300 mg was administered subcutaneously on day 1, day 90, and every six months thereafter. At day 510 (the primary endpoint):

• ORION-10: inclisiran reduced LDL-C by 52.3% vs. Placebo (P<0.001) [9]
• ORION-11: inclisiran reduced LDL-C by 49.9% vs. Placebo (P<0.001) [9]

Time-averaged LDL-C reduction from day 90 to day 540 was 53.8% in ORION-10 and 49.4% in ORION-11 [9]. That "time-averaged" metric matters clinically: it captures how much LDL-C reduction a patient actually experienced across the entire treatment interval, not just at a single snapshot.

Safety data across both trials showed inclisiran was well tolerated. Injection-site adverse events occurred in 2.6% of inclisiran patients vs. 0.9% of placebo patients, and none were classified as severe [9].

ORION-8: Five-Year Extension Data

ORION-8 is the open-label extension study pooling participants from multiple ORION trials. Data presented at the 2023 European Society of Cardiology Congress and published in the Lancet showed sustained LDL-C reductions of approximately 50% at month 60, with no evidence of tachyphylaxis or attenuation [10]. The consistency of effect across 60 months distinguishes inclisiran from earlier PCSK9 monoclonal antibodies, which showed no long-term attenuation either, but required every-two-week or monthly injections rather than twice-yearly dosing.

Adherence Is the Central Durability Driver

Pharmacological durability and patient-level durability are two different things. Inclisiran wins the patient-level durability contest because the dosing schedule removes daily decision-making from the equation.

Real-World Statin Persistence Data

A large pharmacy claims analysis covering 219,108 statin initiators found that only 57.3% of patients were still filling prescriptions at six months, and 42.6% at 12 months [8]. Rosuvastatin performed slightly better than simvastatin or pravastatin in that cohort, but the attrition pattern was similar across all statins. Patients who do not take their medication daily do not maintain the LDL-C reductions seen in trials.

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease states: "Adherence to lifestyle and medication is essential to achieving cardiovascular risk reduction goals. Clinicians should assess and reinforce adherence at every visit." [11] That guidance implicitly acknowledges that adherence is not guaranteed.

Why Twice-Yearly Dosing Changes the Math

When a patient receives inclisiran in a clinic or physician's office, that dose is administered by a healthcare provider. There is no pill to remember, no refill to pick up, and no daily barrier to therapy. The ORION trials achieved greater than 97% dose delivery across all scheduled injection visits in the trial setting [9], a figure no oral statin has matched in real-world practice.

That structural adherence advantage means that even if inclisiran's pharmacological LDL-C lowering were modestly inferior to rosuvastatin 40 mg on a milligram-for-milligram basis, the real-world durability outcome would likely favor inclisiran for patients with prior adherence difficulties.

Comparing Absolute LDL-C Reductions Head to Head

No randomized head-to-head trial has directly compared rosuvastatin monotherapy to inclisiran monotherapy in the same population. The comparison below synthesizes data from trial programs using comparable baseline LDL-C levels.

Rosuvastatin Dose-Response Summary

| Dose | Average LDL-C Reduction | Trial / Source | |---|---|---| | 5 mg daily | approximately 38% | FDA prescribing information [4] | | 10 mg daily | approximately 43% | FDA prescribing information [4] | | 20 mg daily | approximately 52% | JUPITER [2] | | 40 mg daily | approximately 55 to 63% | FDA prescribing information [4] |

Inclisiran Efficacy Summary

| Trial | Population | LDL-C Reduction at Day 510 | |---|---|---| | ORION-10 | ASCVD, on statin | 52.3% [9] | | ORION-11 | ASCVD/risk-equivalent, on statin | 49.9% [9] | | ORION-8 (month 60) | Extension cohort | approximately 50% [10] |

The absolute LDL-C reductions are numerically similar between rosuvastatin 20 to 40 mg and inclisiran 300 mg when adherence is assumed to be perfect. The divergence emerges at 6, 12, and 24 months in clinical practice.

What the ACC/AHA Guidelines Say About Combination Therapy

The 2018 ACC/AHA Cholesterol Guideline (updated 2022) places high-intensity statin therapy as the foundation of LDL-C lowering in very high-risk ASCVD patients, with ezetimibe added next, and then PCSK9 inhibition for patients who remain above 70 mg/dL on maximally tolerated statin plus ezetimibe [12]. Inclisiran is classified within that PCSK9 inhibitor tier. The guideline does not endorse replacing a statin with inclisiran as first-line therapy; it positions inclisiran as an add-on agent.

That positioning reflects a regulatory reality: inclisiran's approval in ASCVD and HeFH populations was studied on top of background statin therapy, not as a standalone replacement.

Switching from Crestor to Leqvio: Clinical Scenarios

Switching rosuvastatin to inclisiran outright is not consistent with current labeling or guidelines. The clinically rational scenarios involve either adding inclisiran to background rosuvastatin or transitioning statin-intolerant patients to an inclisiran-based regimen.

Scenario 1: Adding Inclisiran to Rosuvastatin

For patients with established ASCVD already on rosuvastatin 20 to 40 mg but with LDL-C persistently above 70 mg/dL, adding inclisiran 300 mg twice yearly is guideline-concordant [12]. The ORION trial populations were approximately 90% on background statin therapy, so the efficacy data directly support this combination.

Expected incremental LDL-C reduction from inclisiran added to a moderate-to-high intensity statin: approximately 50% from the statin-treated baseline [9]. If rosuvastatin has already brought LDL-C from 160 mg/dL to 85 mg/dL, adding inclisiran may reduce it to approximately 42 mg/dL, which is within the range recommended for very-high-risk ASCVD patients [12].

Scenario 2: Statin-Intolerant Patients

Statin-associated muscle symptoms (SAMS) affect an estimated 5 to 10% of statin users in clinical practice, though blinded rechallenge trials suggest true pharmacological intolerance is lower [13]. For patients with documented intolerance to multiple statins at multiple doses, inclisiran plus ezetimibe (without a statin) is an off-label but clinically considered strategy. Data from the ORION-7 trial in patients with SAMS and severe hypercholesterolemia showed 46.1% LDL-C reduction with inclisiran alone at day 180 [14].

Clinicians should document intolerance to at least two statins at the lowest available dose before considering a statin-free inclisiran regimen, consistent with ACC guidance on statin intolerance workup [13].

Scenario 3: Adherence-Challenged Patients on Rosuvastatin

Patients with documented non-adherence to daily rosuvastatin (confirmed by refill gaps or pill counts) represent a group where switching the delivery mechanism, rather than the mechanism of action, may be the primary clinical goal. In this scenario, transitioning to inclisiran administered in-office every six months replaces the daily adherence burden with a biannual clinical encounter.

A 2023 real-world analysis from the UK Biobank-linked primary care database found that patients who switched to in-office PCSK9 inhibitor injections maintained LDL-C goals at 12 months at a rate 2.3 times higher than those who remained on daily oral therapy with a history of prior gaps [15].

Safety and Tolerability Over the Long Term

Long-term safety is a dimension of durability. A drug that produces good LDL-C responses but is discontinued due to side effects has poor real-world durability regardless of its pharmacological half-life.

Rosuvastatin Long-Term Safety

Rosuvastatin's 20-plus-year post-marketing record is extensive. The primary safety signals are myopathy (0.1% incidence at standard doses) and new-onset diabetes, which was noted in JUPITER at a hazard ratio of 1.25 (P=0.01) [2]. The absolute excess was approximately 3 additional diabetes cases per 1,000 patient-years of treatment, a risk the American Diabetes Association and ACC consider acceptable given cardiovascular benefit in high-risk patients [11]. Rhabdomyolysis is rare at a frequency below 0.01% [4].

Renal and hepatic function monitoring is recommended at baseline; routine repeat testing is not required unless symptomatic [4].

Inclisiran Long-Term Safety

Across the ORION program through 60 months, inclisiran showed no hepatotoxicity signal, no elevation in creatine kinase, and no increase in new-onset diabetes [10]. Injection-site reactions occurred in 2.6% of patients in the Phase 3 trials, almost all grade 1 or 2 [9]. No neutralizing anti-drug antibodies were detected that meaningfully affected pharmacodynamic response.

One theoretical concern with RNA interference therapies is off-target silencing. Through five years of follow-up in ORION-8, no off-target silencing signal has been identified in reported outcomes [10].

Cost, Access, and the Real-World Durability Equation

Rosuvastatin 20 mg is available as a generic at approximately $10 to 20 per month in the United States. Inclisiran (brand only through 2037 patent) lists at approximately $6,500 per year wholesale acquisition cost. Insurance prior authorization is typically required, and approval rates vary by payer and indication.

Cost is a durability variable. Patients who cannot afford inclisiran will not receive it consistently. The FDA's approval was accompanied by no specific copay cap program at launch, though Novartis has offered patient assistance programs [7]. Prescribers should verify coverage before initiating, as a failed prior authorization followed by a coverage gap would negate the adherence advantage entirely.

The value proposition for inclisiran strengthens in populations where the downstream cost of a recurrent MI or stroke exceeds the drug acquisition cost. A 2022 cost-effectiveness analysis in JACC found inclisiran fell below the $150,000 per QALY threshold in patients with prior MI and LDL-C above 70 mg/dL on maximally tolerated statin [16].

Monitoring LDL-C Durability in Practice

For Patients on Rosuvastatin

Check a fasting lipid panel four to twelve weeks after initiation or dose adjustment to confirm response [12]. Thereafter, annual monitoring is sufficient in stable patients. A single LDL-C check does not reflect time-averaged exposure; if a patient admits to intermittent adherence, the LDL-C value at the clinic visit underestimates the true time-averaged level.

For Patients on Inclisiran

Because inclisiran's mechanism peaks at approximately 30 days post-injection and sustains through the six-month interval, the optimal monitoring window is at the next scheduled injection visit [9]. Check LDL-C immediately before the second or third injection (day 90 or day 270) to confirm response. A value at nadir (day 30 post-injection) overestimates average effect; a value just before the next dose (month 6) reflects the trough, which is still approximately 35 to 40% below baseline [9].

The ACC/AHA 2022 update recommends checking LDL-C one to three months after starting any new lipid-lowering therapy and then every six to twelve months to assess persistence of response [12].